Comparative in-vitro activity of RP 59500 against clinical bacterial isolates.
The activity of RP 59500 against Gram-positive cocci was determined by an agar dilution method and compared with that of erythromycin, cefotaxime and ampicillin. Of the 344 clinical isolates tested, none was resistant to RP 59500; this compound was active both against methicillin-resistant Staphylococcus aureus and against macrolide-resistant Gram-positive cocci. The bactericidal activity of RP 59500 was confirmed by killing curve determinations.
Inoue
M
M
Department of Microbiology, Kitasato University School of Medicine, Japan.
Okamoto
R
R
Okubo
T
T
Inoue
K
K
Mitsuhashi
S
S
D000667:Ampicillin / Q000494:pharmacology; D002439:Cefotaxime / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D014769:Virginiamycin / Q000494:pharmacology*
D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D004917:Erythromycin; D000667:Ampicillin; D002439:Cefotaxime